Ten years after the ABC-02 trial, the U.S. Food and Drug Administration (FDA) approved the first targeted therapy for previously treated patients with unresectable cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, based on the results of the FIGHT-202 trial [11]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.